IHC analysis of primary tumour tissues from 55 out of 111 patients who participated in the randomised phase II TAMRAD study (Treilleux et al. 2015) has shown that high levels of p-4EBP1 as well as low levels of p-AKT(Ser473) were associated with improved time-to-progression (TTP) on everolimus plus tamoxifen compared to that on tamoxifen alone. The gene discussed is EIF4EBP1; the disease is neoplasm.